Boris Freidlin

Best Publications

• Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

  Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  1163
  Citations

• Accelerated Titration Designs for Phase I Clinical Trials in Oncology

  Richard Simon;Boris Freidlin;Larry Rubinstein;Susan G. Arbuck

  883
  Citations

• Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results

  Oscar S. Breathnach;Boris Freidlin;Barbara Conley;Mark R. Green

  496
  Citations

• Trend tests for case-control studies of genetic markers: power, sample size and robustness.

  Boris Freidlin;Gang Zheng;Zhaohai Li;Joseph L. Gastwirth

  484
  Citations

• Randomized Clinical Trials With Biomarkers: Design Issues

  Boris Freidlin;Lisa M. McShane;Edward L. Korn

  478
  Citations

• Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

  Lawrence V. Rubinstein;Edward L. Korn;Boris Freidlin;Sally Hunsberger

  443
  Citations

• Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

  Unknown

  384
  Citations

• Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

  Wenyu Jiang;Boris Freidlin;Richard Simon

  332
  Citations

• Outcome-Adaptive Randomization: Is It Useful?

  Edward L. Korn;Boris Freidlin

  263
  Citations

• The Cross-Validated Adaptive Signature Design

  Boris Freidlin;Wenyu Jiang;Richard Simon

  244
  Citations

• Biomarker enrichment strategies: matching trial design to biomarker credentials

  Boris Freidlin;Edward L. Korn

  209
  Citations

• Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

  Lori E. Dodd;Edward L. Korn;Boris Freidlin;C. Carl Jaffe

  203
  Citations

• Multi-Arm Clinical Trials of New Agents: Some Design Considerations

  Boris Freidlin;Edward L. Korn;Robert Gray;Alison Martin

  184
  Citations

• Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers

  Mei Yin C. Polley;Boris Freidlin;Edward L. Korn;Barbara A. Conley

  183
  Citations

• Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

  Edward L. Korn;Boris Freidlin;Jeffrey S. Abrams

  173
  Citations

• Robust Genomic Control for Association Studies

  Gang Zheng;Boris Freidlin;Joseph L. Gastwirth

  117
  Citations

• Randomized Phase II Trial Designs With Biomarkers

  Boris Freidlin;Lisa M. McShane;Mei Yin C. Polley;Edward L. Korn

  112
  Citations

• Should the Median Test be Retired from General Use

  Boris Freidlin;Joseph L. Gastwirth

  106
  Citations

• Choice of scores in trend tests for case-control studies of candidate-gene associations

  Gang Zheng;Boris Freidlin;Zhaohai Li;Joseph L. Gastwirth

  100
  Citations

• Borrowing Information across Subgroups in Phase II Trials: Is It Useful?

  Boris Freidlin;Edward L. Korn

  98
  Citations